KROS Earnings — Keros Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
KROS — Keros Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$11.25
Market Cap$222.7M
P/E—
52W Range$9.79 – $22.55
Next Earnings2026-08-05
About Keros Therapeutics, Inc. Common Stock
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
